Switch to:
Also traded in: Austria, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.25
NAS:ESRX's Cash-to-Debt is ranked lower than
89% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.15 vs. NAS:ESRX: 0.25 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ESRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.28 Max: No Debt
Current: 0.25
0.03
No Debt
Equity-to-Asset 0.37
NAS:ESRX's Equity-to-Asset is ranked lower than
63% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.38 vs. NAS:ESRX: 0.37 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ESRX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.11  Med: 0.34 Max: 0.72
Current: 0.37
0.11
0.72
Debt-to-Equity 0.73
NAS:ESRX's Debt-to-Equity is ranked lower than
84% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.59 vs. NAS:ESRX: 0.73 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:ESRX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05  Med: 0.89 Max: 4.16
Current: 0.73
0.05
4.16
Debt-to-EBITDA 2.04
NAS:ESRX's Debt-to-EBITDA is ranked lower than
56% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.82 vs. NAS:ESRX: 2.04 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:ESRX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.08  Med: 2.3 Max: 3.39
Current: 2.04
1.08
3.39
Interest Coverage 8.56
NAS:ESRX's Interest Coverage is ranked lower than
52% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 10.81 vs. NAS:ESRX: 8.56 )
Ranked among companies with meaningful Interest Coverage only.
NAS:ESRX' s Interest Coverage Range Over the Past 10 Years
Min: 4.51  Med: 7.71 Max: 16.5
Current: 8.56
4.51
16.5
Piotroski F-Score: 8
Altman Z-Score: 3.47
Beneish M-Score: -2.39
WACC vs ROIC
7.49%
17.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 5.27
NAS:ESRX's Operating Margin % is ranked higher than
52% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 5.49 vs. NAS:ESRX: 5.27 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ESRX' s Operating Margin % Range Over the Past 10 Years
Min: 2.98  Med: 4.81 Max: 6.06
Current: 5.27
2.98
6.06
Net Margin % 4.83
NAS:ESRX's Net Margin % is ranked higher than
63% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.87 vs. NAS:ESRX: 4.83 )
Ranked among companies with meaningful Net Margin % only.
NAS:ESRX' s Net Margin % Range Over the Past 10 Years
Min: 1.4  Med: 2.7 Max: 4.83
Current: 4.83
1.4
4.83
ROE % 26.51
NAS:ESRX's ROE % is ranked higher than
85% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 15.89 vs. NAS:ESRX: 26.51 )
Ranked among companies with meaningful ROE % only.
NAS:ESRX' s ROE % Range Over the Past 10 Years
Min: 8.16  Med: 23.28 Max: 87.47
Current: 26.51
8.16
87.47
ROA % 9.11
NAS:ESRX's ROA % is ranked higher than
75% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 4.25 vs. NAS:ESRX: 9.11 )
Ranked among companies with meaningful ROA % only.
NAS:ESRX' s ROA % Range Over the Past 10 Years
Min: 3.3  Med: 7.51 Max: 14.42
Current: 9.11
3.3
14.42
ROC (Joel Greenblatt) % 404.83
NAS:ESRX's ROC (Joel Greenblatt) % is ranked higher than
84% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 65.45 vs. NAS:ESRX: 404.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ESRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 220.38  Med: 402.33 Max: 589.99
Current: 404.83
220.38
589.99
3-Year Revenue Growth Rate 8.90
NAS:ESRX's 3-Year Revenue Growth Rate is ranked higher than
61% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 8.60 vs. NAS:ESRX: 8.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ESRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.3  Med: 23.8 Max: 86.2
Current: 8.9
5.3
86.2
3-Year EBITDA Growth Rate 17.50
NAS:ESRX's 3-Year EBITDA Growth Rate is ranked higher than
60% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.70 vs. NAS:ESRX: 17.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ESRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 15  Med: 24.8 Max: 66
Current: 17.5
15
66
3-Year EPS without NRI Growth Rate 43.10
NAS:ESRX's 3-Year EPS without NRI Growth Rate is ranked higher than
81% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 17.70 vs. NAS:ESRX: 43.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ESRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 28.1 Max: 74.6
Current: 43.1
0
74.6
GuruFocus has detected 2 Warning Signs with Express Scripts Holding Co NAS:ESRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ESRX's 30-Y Financials

Financials (Next Earnings Date: 2019-02-14 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

ESRX Guru Trades in Q3 2017

Diamond Hill Capital 3,253 sh (New)
Caxton Associates 3,300 sh (New)
Paul Tudor Jones 44,496 sh (+98.07%)
First Pacific Advisors 54,100 sh (+35.25%)
Joel Greenblatt 865,757 sh (+26.91%)
Richard Pzena 3,509,800 sh (+23.63%)
Ken Fisher 349,564 sh (+3.09%)
Yacktman Asset Management 15,200 sh (unchged)
First Eagle Investment 1,168 sh (unchged)
Seth Klarman 2,556,891 sh (unchged)
David Dreman 15,063 sh (unchged)
Steven Cohen 200,000 sh (unchged)
Jeremy Grantham Sold Out
Jeff Auxier 84,557 sh (-0.18%)
Ronald Muhlenkamp 61,215 sh (-1.23%)
Ray Dalio 596,933 sh (-2.55%)
Dodge & Cox 34,938,393 sh (-3.45%)
Chris Davis 3,848,419 sh (-4.06%)
Manning & Napier Advisors, Inc 2,058,410 sh (-6.96%)
Barrow, Hanley, Mewhinney & Strauss 18,704,089 sh (-7.89%)
Mario Gabelli 11,940 sh (-19.11%)
Charles Brandes 1,675,423 sh (-24.98%)
David Rolfe 46,900 sh (-26.55%)
» More
Q4 2017

ESRX Guru Trades in Q4 2017

Pioneer Investments 627,178 sh (New)
Leucadia National 7,597 sh (New)
Glenn Greenberg 7,080 sh (New)
Jeff Ubben 1,200,000 sh (New)
Richard Pzena 3,602,780 sh (+2.65%)
Charles Brandes 1,718,420 sh (+2.57%)
Chris Davis 3,916,700 sh (+1.77%)
Jeff Auxier 84,874 sh (+0.37%)
Yacktman Asset Management 15,200 sh (unchged)
First Eagle Investment 1,168 sh (unchged)
David Dreman 15,063 sh (unchged)
Steven Cohen 138,100 sh (unchged)
Caxton Associates Sold Out
Dodge & Cox 34,767,794 sh (-0.49%)
Ronald Muhlenkamp 60,439 sh (-1.27%)
Diamond Hill Capital 3,207 sh (-1.41%)
Mario Gabelli 11,200 sh (-6.20%)
Barrow, Hanley, Mewhinney & Strauss 17,095,646 sh (-8.60%)
Seth Klarman 2,306,456 sh (-9.79%)
Paul Tudor Jones 39,962 sh (-10.19%)
Ken Fisher 302,322 sh (-13.51%)
David Rolfe 40,400 sh (-13.86%)
Joel Greenblatt 710,916 sh (-17.89%)
First Pacific Advisors 6,250 sh (-88.45%)
Ray Dalio 23,259 sh (-96.10%)
» More
Q1 2018

ESRX Guru Trades in Q1 2018

Jim Simons 1,398,039 sh (New)
Jeremy Grantham 208,300 sh (New)
George Soros 30,500 sh (New)
Larry Robbins 4,641,986 sh (New)
Leucadia National 24,251 sh (+219.22%)
Ronald Muhlenkamp 129,559 sh (+114.36%)
Ken Fisher 401,090 sh (+32.67%)
Paul Tudor Jones 51,770 sh (+29.55%)
Joel Greenblatt 768,923 sh (+8.16%)
Pioneer Investments 638,424 sh (+1.79%)
Dodge & Cox 34,977,619 sh (+0.60%)
David Dreman 15,063 sh (unchged)
Yacktman Asset Management 15,200 sh (unchged)
Mario Gabelli 11,200 sh (unchged)
Diamond Hill Capital Sold Out
First Pacific Advisors Sold Out
Seth Klarman Sold Out
Glenn Greenberg Sold Out
Ray Dalio Sold Out
David Rolfe Sold Out
Jeff Ubben Sold Out
First Eagle Investment Sold Out
Jeff Auxier 84,834 sh (-0.05%)
Richard Pzena 3,106,946 sh (-13.76%)
Barrow, Hanley, Mewhinney & Strauss 14,404,431 sh (-15.74%)
Charles Brandes 1,424,677 sh (-17.09%)
Chris Davis 385,436 sh (-90.16%)
» More
Q2 2018

ESRX Guru Trades in Q2 2018

John Hussman 35,800 sh (New)
David Abrams 2,653,101 sh (New)
Glenn Greenberg 1,249,627 sh (New)
Jeremy Grantham 1,320,908 sh (+534.14%)
George Soros 85,200 sh (+179.34%)
Leucadia National 46,824 sh (+93.08%)
Paul Tudor Jones 80,985 sh (+56.43%)
Larry Robbins 6,979,569 sh (+50.36%)
Pioneer Investments 807,517 sh (+26.49%)
Dodge & Cox 41,463,656 sh (+18.54%)
Ken Fisher 416,456 sh (+3.83%)
Chris Davis 387,178 sh (+0.45%)
Jeremy Grantham 217,000 sh (unchged)
Yacktman Asset Management Sold Out
Jim Simons Sold Out
Ronald Muhlenkamp 129,511 sh (-0.04%)
Richard Pzena 3,103,548 sh (-0.11%)
Jeff Auxier 84,740 sh (-0.11%)
Charles Brandes 1,394,914 sh (-2.09%)
Barrow, Hanley, Mewhinney & Strauss 13,799,574 sh (-4.20%)
Mario Gabelli 8,200 sh (-26.79%)
Joel Greenblatt 429,168 sh (-44.19%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ESRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Express Scripts Holding Co does not have enough historical financial data to display Peter Lynch Chart.

Business Description

Industry: Health Care Plans » Health Care Plans    NAICS: 446110    SIC: 5912
Compare:NYSE:CI, NYSE:HUM, NYSE:AET, NYSE:ANTM, NYSE:CNC, NYSE:CVS, NYSE:WCG, NYSE:MOH, BSP:ODPV3, BSP:QUAL3, NAS:MGLN, XPAR:GDS, NAS:HIIQ, OSTO:MCOV B, ROCO:6665, ATH:IATR, ASX:ONT, TSXV:NAC, MIL:HI, OTCPK:HFRN » details
Traded in other countries:ESRX.Austria, ESRX34.Brazil, 4XS.Germany, ESRX.Mexico, ESRX.Switzerland, 0R0W.UK,
Headquarter Location:USA
Express Scripts Holding Co is a pharmacy benefit manager in the United States. It offers healthcare management and administration services such as managed care organizations, health insurers, workers' compensation plans and government health programs.

Express Scripts is the largest pharmacy benefit manager in the United States. Through its mail-order pharmacy and network of retail pharmacies, Express Scripts processes approximately 1.3 billion adjusted prescriptions annually for its payer clients.

Guru Investment Theses on Express Scripts Holding Co

Jeff Auxier Comments on Express Scripts Holding - Nov 08, 2018

Express Scripts Holding Co. (NASDAQ:ESRX) 23.05% Cigna is acquiring pharmacy benefit manager Express Scripts for an estimated $67B or over $95 a share. The deal includes $48.75 in cash and 0.2434 shares of Cigna for each share of Express Scripts and is expected to close by the end of the year. We originally invested in ESRX at $7.63 a share after a face-to-face meeting with management late on a Friday.



From Jeff Auxier (Trades, Portfolio)'s third-quarter 2018 shareholder commentary.

Check out Jeff Auxier latest stock trades

Jeff Auxier Comments on Express Scripts - Feb 06, 2018

Express Scripts (NASDAQ:ESRX) recently acquired eviCore Healthcare, an industry leader in evidence-based medical benefit management services. EviCore helps manage medical benefits for 100 million people, and Express Scripts expects the acquisition to be accretive to adjusted diluted earnings per share in 2018, which they now estimate in the range of $7.67 to $7.87. At a P/E of 12 times 2018 the stock seems very cheap.







From Jeff Auxier (Trades, Portfolio)'s fourth quarter 2018 shareholder letter.

Check out Jeff Auxier latest stock trades

Weitz Funds Comments on Express Scripts - Jan 26, 2017

Express Scripts (NASDAQ:ESRX) is the largest stand-alone pharmacy benefits manager (PBM) in the U.S., helping health benefit providers improve access to (and the affordability of) prescription drugs. The ongoing impasse with its largest customer (Anthem), an evolving competitive landscape, and public finger pointing between so-called middlemen and drug manufacturers as to the source of persistent drug inflation led us to (once again) test the assumptions underlying our notion of Express’s business value. Our additional diligence suggested an increased probability of Anthem not renewing with Express Scripts in 2019. In addition, the likelihood that competitive or industry pressures offset a portion (potentially even all) of other future profit-per-script drivers seem to have increased, particularly for Express. This combination made the risk-reward trade-off less compelling, and we elected to close our position in Express across the funds following the post-election rally in November.



  • From Weitz Investment Management's Value Fund 4th quarter 2016 commentary.


Check out Wallace Weitz latest stock trades

Top Ranked Articles about Express Scripts Holding Co

Express Scripts Introduces Novel Formulary Built for Evolution of Drug Pricing
Jeff Auxier Comments on Express Scripts Holding Guru stock highlight
Express Scripts Holding Co. (NASDAQ:ESRX) 23.05% Cigna is acquiring pharmacy benefit manager Express Scripts for an estimated $67B or over $95 a share. The deal includes $48.75 in cash and 0.2434 shares of Cigna for each share of Express Scripts and is expected to close by the end of the year. We originally invested in ESRX at $7.63 a share after a face-to-face meeting with management late on a Friday.
Read more...
Express Scripts' myMatrixx Launches myDataSense Analytics Tool
Express Scripts' Innovative Advanced Opioid Management Solution Shifts First-Time Opioid Users to Safer, Short-Term Prescriptions
National Drug Purchasing Coalition - member companies include PepsiCo, Inc. and ExxonMobil - and Express Scripts Team Up to Create New Pharmacy Benefit Design for Greater Performance Accountability, Transparency, and Alignment
Express Scripts Offers New Value-Based Program for Migraine
Express Scripts Holding Company Announces Third Quarter 2018 Earnings Release Details
Express Scripts Readies Emergency Support for Impacted Members in Advance of Hurricane Michael
Express Scripts Readies Emergency Support for Impacted Members in Advance of Hurricane Michael
Express Scripts Introduces Medicare Part D Plan Offerings for 2019

Ratios

vs
industry
vs
history
PE Ratio 11.43
ESRX's PE Ratio is ranked higher than
95% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.79 vs. ESRX: 11.43 )
Ranked among companies with meaningful PE Ratio only.
ESRX' s PE Ratio Range Over the Past 10 Years
Min: 8.31  Med: 24.99 Max: 36.23
Current: 11.43
8.31
36.23
Forward PE Ratio 10.30
ESRX's Forward PE Ratio is ranked higher than
92% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 14.27 vs. ESRX: 10.30 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 11.43
ESRX's PE Ratio without NRI is ranked higher than
95% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 19.79 vs. ESRX: 11.43 )
Ranked among companies with meaningful PE Ratio without NRI only.
ESRX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.31  Med: 24.62 Max: 35.5
Current: 11.43
8.31
35.5
Price-to-Owner-Earnings 14.31
ESRX's Price-to-Owner-Earnings is ranked higher than
94% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.47 vs. ESRX: 14.31 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ESRX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.68  Med: 13.36 Max: 27.84
Current: 14.31
5.68
27.84
PB Ratio 2.68
ESRX's PB Ratio is ranked higher than
73% of the 26 Companies
in the Global Health Care Plans industry.

( Industry Median: 3.42 vs. ESRX: 2.68 )
Ranked among companies with meaningful PB Ratio only.
ESRX' s PB Ratio Range Over the Past 10 Years
Min: 1.85  Med: 3.07 Max: 29.46
Current: 2.68
1.85
29.46
PS Ratio 0.55
ESRX's PS Ratio is ranked higher than
72% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.73 vs. ESRX: 0.55 )
Ranked among companies with meaningful PS Ratio only.
ESRX' s PS Ratio Range Over the Past 10 Years
Min: 0.34  Med: 0.57 Max: 1.07
Current: 0.55
0.34
1.07
Price-to-Free-Cash-Flow 13.75
ESRX's Price-to-Free-Cash-Flow is ranked higher than
89% of the 18 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.78 vs. ESRX: 13.75 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ESRX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.7  Med: 12.95 Max: 25.56
Current: 13.75
5.7
25.56
Price-to-Operating-Cash-Flow 12.72
ESRX's Price-to-Operating-Cash-Flow is ranked higher than
80% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 12.15 vs. ESRX: 12.72 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ESRX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.46  Med: 12.12 Max: 23.25
Current: 12.72
5.46
23.25
EV-to-EBIT 12.21
ESRX's EV-to-EBIT is ranked higher than
81% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.89 vs. ESRX: 12.21 )
Ranked among companies with meaningful EV-to-EBIT only.
ESRX' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.2  Med: 15 Max: 30.2
Current: 12.21
8.2
30.2
EV-to-EBITDA 8.96
ESRX's EV-to-EBITDA is ranked higher than
81% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 9.81 vs. ESRX: 8.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
ESRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.1  Med: 11.4 Max: 22.4
Current: 8.96
6.1
22.4
EV-to-Revenue 0.65
ESRX's EV-to-Revenue is ranked higher than
67% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.01 vs. ESRX: 0.65 )
Ranked among companies with meaningful EV-to-Revenue only.
ESRX' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.4  Med: 0.7 Max: 1.2
Current: 0.65
0.4
1.2
PEG Ratio 0.74
ESRX's PEG Ratio is ranked higher than
77% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.35 vs. ESRX: 0.74 )
Ranked among companies with meaningful PEG Ratio only.
ESRX' s PEG Ratio Range Over the Past 10 Years
Min: 0.43  Med: 0.98 Max: 1.69
Current: 0.74
0.43
1.69
Shiller PE Ratio 26.44
ESRX's Shiller PE Ratio is ranked higher than
77% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 27.53 vs. ESRX: 26.44 )
Ranked among companies with meaningful Shiller PE Ratio only.
ESRX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.5  Med: 42.76 Max: 79.91
Current: 26.44
19.5
79.91
Current Ratio 0.77
ESRX's Current Ratio is ranked lower than
84% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.35 vs. ESRX: 0.77 )
Ranked among companies with meaningful Current Ratio only.
ESRX' s Current Ratio Range Over the Past 10 Years
Min: 0.55  Med: 0.9 Max: 5.57
Current: 0.77
0.55
5.57
Quick Ratio 0.65
ESRX's Quick Ratio is ranked lower than
80% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.35 vs. ESRX: 0.65 )
Ranked among companies with meaningful Quick Ratio only.
ESRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.47  Med: 0.8 Max: 4.78
Current: 0.65
0.47
4.78
Days Inventory 8.43
ESRX's Days Inventory is ranked higher than
55% of the 11 Companies
in the Global Health Care Plans industry.

( Industry Median: 7.84 vs. ESRX: 8.43 )
Ranked among companies with meaningful Days Inventory only.
ESRX' s Days Inventory Range Over the Past 10 Years
Min: 3.02  Med: 5.49 Max: 8.43
Current: 8.43
3.02
8.43
Days Sales Outstanding 14.66
ESRX's Days Sales Outstanding is ranked higher than
80% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 30.58 vs. ESRX: 14.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
ESRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.11  Med: 15.16 Max: 24.11
Current: 14.66
14.11
24.11
Days Payable 17.43
ESRX's Days Payable is ranked lower than
87% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 42.32 vs. ESRX: 17.43 )
Ranked among companies with meaningful Days Payable only.
ESRX' s Days Payable Range Over the Past 10 Years
Min: 5.7  Med: 11.91 Max: 17.43
Current: 17.43
5.7
17.43

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 8.10
ESRX's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: -0.50 vs. ESRX: 8.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ESRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.4  Med: -0.5 Max: 8.1
Current: 8.1
-14.4
8.1

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.71
ESRX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
87% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.08 vs. ESRX: 0.71 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ESRX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.49  Med: 1.36 Max: 62.6
Current: 0.71
0.49
62.6
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.49
ESRX's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
89% of the 9 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.02 vs. ESRX: 0.49 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
ESRX' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.37  Med: 1.79 Max: 2.99
Current: 0.49
0.37
2.99
Price-to-Median-PS-Value 0.96
ESRX's Price-to-Median-PS-Value is ranked higher than
74% of the 23 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.19 vs. ESRX: 0.96 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ESRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.55  Med: 1.05 Max: 6
Current: 0.96
0.55
6
Price-to-Peter-Lynch-Fair-Value 0.76
ESRX's Price-to-Peter-Lynch-Fair-Value is ranked higher than
91% of the 11 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.09 vs. ESRX: 0.76 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ESRX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.38  Med: 1.09 Max: 2.44
Current: 0.76
0.38
2.44
Earnings Yield (Greenblatt) % 8.19
ESRX's Earnings Yield (Greenblatt) % is ranked higher than
86% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 6.22 vs. ESRX: 8.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ESRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.3  Med: 6.7 Max: 12.2
Current: 8.19
3.3
12.2
Forward Rate of Return (Yacktman) % 22.37
ESRX's Forward Rate of Return (Yacktman) % is ranked higher than
69% of the 16 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.01 vs. ESRX: 22.37 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ESRX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 22.2  Med: 24.6 Max: 27.6
Current: 22.37
22.2
27.6

More Statistics

Revenue (TTM) (Mil) $101,353.20
EPS (TTM) $ 8.56
Beta0.93
Volatility22.60%
52-Week Range $59.25 - 100.43
Shares Outstanding (Mil)563.86

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 101,371 102,754
EBIT (Mil $) 6,682 6,898
EBITDA (Mil $) 7,858 7,948
EPS ($) 7.63 8.13
EPS without NRI ($) 7.63 8.13
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.03%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 88
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}